Streetbeat News

Regulatory

XERI

Xeriant has provided an update on the production and certification of its eco-friendly NEXBOARD construction panels. The company has executed a second pilot production run with a U.S. contract manufacturer and is enhancing panel properties through internal and third-party testing. Modifications are being finalized to improve weight and rigidity.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:16 pm

STLA

Stellantis NV (NYSE:STLA) has warned the UK government that it may cease vehicle production in the country if the government does not relax its electric vehicle (EV) sales targets. Stellantis has invested £100 million to convert its Ellesmere Port factory into an electric-only plant but finds the current EV sales targets 'unsustainable.'

Portfolio Pulse from Rounak Jain

June 25, 2024 | 12:12 pm

BIVI

BioVie Inc. presented the protocol design for its upcoming SUNRISE-PD Phase 2 trial of bezisterim (NE3107) in early Parkinson's disease patients at the ATMRD 2024 Congress. The trial will evaluate the drug's effect on motor and non-motor symptoms in approximately 60 patients. Data from an earlier Phase 2a trial were also highlighted.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:11 pm

DJT

Trump Media & Technology Group Corp (NASDAQ:DJT) saw a significant surge of over 21% on Monday, recovering from a decline following Trump's legal issues. The stock closed at $33.52, up from $27 on Friday. The company expects to generate over $69.4 million from exercised warrants, but concerns about stock dilution remain. Short sellers have faced substantial losses, totaling $178 million year-to-date. Trump is also set to speak at the Bitcoin 2024 convention, highlighting his pro-crypto stance.

Portfolio Pulse from Anusuya Lahiri

June 25, 2024 | 12:08 pm

HRMY

The FDA has confirmed a favorable benefit-risk profile for WAKIX, a drug by Harmony Biosciences. The company plans to launch at least one new product or indication annually over the next five years. The denial of a citizen petition further confirms WAKIX's safety and efficacy for treating EDS and cataplexy in adults with narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:07 pm

LPCN

Lipocine announced that its drug LPCN 1154 met the standard bioequivalence criteria and was well tolerated with no sedation or somnolence events. The company is on track for an NDA filing, targeting Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:06 pm

AQST

Aquestive Therapeutics (NASDAQ:AQST) reported positive topline data from a temperature/pH study of its Anaphylm Sublingual Film, showing that pharmacokinetic results were unaffected by oral cavity exposure to liquids of different temperatures and pH. The company remains on track to complete supportive clinical studies and expects to request a pre-NDA meeting with the FDA in Q3 2024, with plans to file a New Drug Application shortly after completing its pediatric study.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:05 pm

TEVA

Teva Pharmaceutical Industries Ltd. announced that its agreement with the Israel Tax Authority will not impact its financial outlook for 2024, which the company has reaffirmed.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:04 pm

SPY

Fed's Bowman indicated that as inflation declines, the Federal Reserve will need to lower interest rates. The focus will be on how subcategories of inflation evolve.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:03 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has announced that it is prioritizing the development of EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The company is advancing pre-clinical development and targeting a pre-IND meeting with the FDA for early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:03 pm